Back to Journals » Clinical Pharmacology: Advances and Applications » Volume 5 » Supplement 1

Epithelial cell-adhesion molecule-directed trifunctional antibody immunotherapy for symptom management of advanced ovarian cancer

Authors Eskander RN, Tewari KS

Received 7 May 2013

Accepted for publication 21 June 2013

Published 3 October 2013 Volume 2013:5(Supplement 1) Pages 55—61


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 7

Download Article [PDF] 

Ramez N Eskander, Krishnansu S Tewari

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Irvine, CA, USA

Abstract: Despite advances in cytotoxic chemotherapy and surgical cytoreduction, disease recurrence continues to be a troubling problem in patients with advanced-stage epithelial ovarian cancer (EOC). Malignant ascites affects approximately 10% of patients with recurrent EOC and is associated with troublesome symptoms, including abdominal pressure, distension, dyspnea, pelvic pain, and bowel/bladder dysfunction. To date, no effective therapy has been identified for the treatment of malignant ascites in patients with recurrent, advanced-stage ovarian cancer. Recently, immune modulation has gained attention as a novel approach to anti-cancer therapy. This review explores the role of epithelial cell-adhesion molecule (EpCAM)-directed immunotherapy, with a specific focus on the mechanism of action of the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3). In addition, clinical trials exploring the use of catumaxomab in the treatment of malignant ascites in patients with ovarian cancer are reviewed.

Keywords: ovarian cancer, immunotherapy, catumaxomab, CD3, EpCAM

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]